NDAORALSYRUP
Approved
Mar 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KENACORT (triamcinolone diacetate) is an oral corticosteroid syrup approved in 1961 for inflammatory and allergic conditions. It is a systemic glucocorticoid that suppresses immune and inflammatory responses across multiple indications. The drug is administered orally and has a well-established safety and efficacy profile spanning over six decades.
LOE Approaching
As LOE approaches, the brand team is likely focused on defending market share and managing competitive pressure rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on KENACORT offers exposure to legacy product management, competitive defense strategies, and mature market dynamics rather than growth-stage innovation. Career advancement may be limited by the product's LOE status, making this role best suited for professionals seeking stability in a well-established therapeutic area or transition to emerging products.
Brand Manager
Worked on KENACORT at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.